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osting by EAbstract Gene therapy of the eye has a high potential of becoming the preferred treatment of a num-
ber of eye diseases. Because of its easy accessibility, all the tissues of the eye can be reached and genet-
ically manipulated with nowadays standard gene delivery technologies. Gene therapy offers the
possibility to do both, correct a genetic defect by replacing the mutated or missing gene and that of
using genes as drugs. Gene drugs would be more speciﬁc and would have a longer duration of action
and less toxicity than conventional drugs. Examples of both applications are beginning to emerge.
Using gene replacement, vision has been restored in several patients of Leber congenital amaurosis
(Maguire et al., 2009). Some gene drugs, such as siRNA, are currently in clinical trials to silence angio-
genic factors in macular degeneration (Campa and Harding, 2011). In this manuscript we ﬁrst give a
short overview of the basics of gene therapy in the eye and then review the ongoing preclinical studies
in our laboratory for the gene-drug treatment of steroid-induced ocular hypertension.
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Glaucoma is an optic neuropathy caused by the degeneration
of the retinal ganglion cells (RGCs). Glaucoma occurs more
frequently in the older population and it is the second cause
of worldwide blindness (Quigley, 1996). Blindness caused by
glaucoma is irreversible. Currently, the only treatment avail-
able for glaucoma is the administration of daily drops or sur-
gery. However, the use of daily drops is practically difﬁcult
and quite cumbersome for an aging individual leading to a
high degree of non compliance. The search for an alternative
treatment where the use of the medication could be reduced
to once or twice a year is highly desirable.
Using genes as drugs could bring us such possibility. Genes,
or fragments of genetic material, can be delivered inside a given
cell and allowed to make their encoded protein for long periods
of time. Because the sequence of the human genome is now com-
plete, theDNAof every single enzyme or protein can be isolated,
cloned and ampliﬁed for an unlimited number of times. Proper
engineering of themolecule and insertion of regulatory elements
in a gene clone can theoretically control its expression and mod-
ulate the targeting and abundance of the wanted product.
Althoughmultiple limiting factors and interferences do still exist
and detract from a perfect outcome, advances in treatment of all
diseases by gene therapy have been staggering.
In glaucoma, the major risk factor is elevated intraocular
pressure (IOP). Elevated IOP is the result of an increased resis-
tance of the trabecular meshwork to the ﬂow of the aqueous
humor as it exits the eye. The trabecular meshwork is a sophis-
ticated spongiform tissue formed by a loose structure of cells
and extracellular matrix (ECM) organized in characteristic
architecture. The tissue is bordered by a one-cell layer which
forms the inner wall of the Schlemm’s canal. Although every
cell layer of the trabecular meshwork could be causing dys-
function, it is well established that the increased resistance in
glaucoma is due in great part to an accumulation of ECM
and the formation of sheath-derived plaque materials (SD-
plaques) (Lu¨tjen-Drecoll, 1973; Lu¨tjen-Drecoll et al., 1986).For the gene therapy treatment of glaucoma we could tar-
get either of the two main tissues: the trabecular meshwork
and the RGC cells. The goal of targeting the trabecular mesh-
work will be to use genes to lower IOP while the goal of target-
ing RGC will be that of using genes to protect the cells from
apoptosis and death (neuroprotection) (Fig. 1).
The correction of a genetic gene defect in glaucoma would
also be possible. However, this approach would most likely be
limited to single severe cases involving young patients. The
mutation would have to be well characterized, and the gene
replacement would have ﬁrst to be conducted in an animal
model exhibiting the same gene mutation and phenotype than
that of the patient.2. Viral vectors and siRNA
2.1. Viral vectors to deliver genetic material to glaucoma-
relevant tissues
There are four gene therapy tools being studied for gene
therapy of glaucoma, three common viral vectors plus an
short interfering RNA (siRNA) (Fig. 2). The viral vectors
are adenoviruses (Ad), adeno-associated viruses (AAV) and
Lentiviruses. All of them have been stripped off their own
pathogenic genetic material and engineered to carry potential
therapeutic gene expression cassettes. The cassettes contain
the gene to be delivered (transgene), a promoter, and possibly
gene regulatory sequences.
Ads are double-stranded DNA vectors, have high tropism
and efﬁciency for the trabecular meshwork; and have high
capacity in their genome to incorporate relative large genes.
In vivo, they induce an inﬂammatory response at high concen-
trations and their duration of expression is short, between 1 to
3 weeks in most animals (Borra´s et al., 2001; Kee et al., 2001).
Though probably not the ﬁnal tool for gene therapy, Ads are
of great use for trabecular meshwork pre-clinical studies. Stud-
ies in our laboratory have investigated Ads carrying potential
Figure 2 Gene therapy tools for the trabecular meshwork. Top three diagrams: genome of the three most common viral vectors being
studied for gene delivery to the glaucoma targeting tissues. Bottom: diagram of the mechanism of silencing a gene by short interfering
RNA (siRNA); small molecules of siRNA bind to the RISC protein and are carried to the target RNA which gets degraded by the RISC
nuclease. As a consequence, the gene is silenced.
Figure 1 Target tissues for glaucomagene drugs.Left: trabecularmeshwork target; top:diagramof ameridional view section of the anterior
segment of a human eye showing the routes of aqueous humorﬂow; bottom: lightmicroscopy photographof ameridional section of a perfused
postmortem human anterior segment at the angle, showing the different cellular regions of the trabecular meshwork and the Schlemm’s canal
(SC). Section stainedwith toluidine blue.Right: retinal ganglion cell (RGC) layer target; top: diagramof ameridional section of the human eye
showing the delivery direction to theRGC; bottom: lightmicroscopy photograph of the human retina showing the different cell layers and and
emphasizing the RGC and nerve ﬁber layer which are those affected by glaucoma. Section stained with eosin and hematoxylin.
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and matrix metallopeptidase 1 (MMP1). These genes were
found to decrease trabecular meshwork outﬂow resistance in
organ culture (Gabelt et al., 2006; Vittitow et al., 2002) andto reduce IOP in living animals (Gerometta et al., 2010; Spiga
and Borra´s, 2010) (see below).
AAV are single-stranded DNA vectors, have high tropism
for the retina, and have the best gene therapy safety record
356 T. Borra´sto date. Once into the cells, AAV can express the transgene for
up to ﬁve years after a single dose (Rivera et al., 2005). An
AAV2 vector carrying the RPE65 gene is currently being used
in clinical trials to reverse congenital blindness caused by a ret-
inal pigmented epithelium cell defect (Stein et al., 2011).
Numerous examples of AAV vectors carrying neuroprotective
genes (such as ciliary neurotrophic factor, CNTF or brain-de-
rived neurotrophic factor, BDNF) and injected intravitreally
have shown to protect RGC from rat hypertensive models
(Hellstrom and Harvey, 2011). Very recently, an exciting study
using systemic delivery of an AAV vector carrying the pig-
ment-derived epithelium factor (PEDF) transgene was able
to protect RGC death in the glaucomatous DBA/2J mouse
(Sullivan et al., 2011).
AAV viral vectors though, do not transduce the trabecu-
lar meshwork due to their inability to form a double
stranded DNA upon entering the cell. However, because
of their high desirability for long-term and safe gene therapy
proﬁle, a second generation AAV vector has been developed,
the self-complementary AAV (scAAV) which overrides the
limiting step. A single intracameral dose of scAAV.GFP in
living monkeys resulted in positive gene delivery to the tra-
becular meshwork with early onset and lasting for at least
two years (Buie et al., 2010) (Fig. 3). These encouraging
ﬁndings are setting the way for safe gene targeting of the
trabecular meshwork.
Lentiviruses are single stranded RNA vectors derived from
human or simian immunodeﬁciency viruses. They integrate
into the host genome and as a result, retain the ability to ex-
press the transgene for a long time. Lentiviruses transduce
both the trabecular meshwork and the RGCs, and these vec-
tors carrying genes for cyclooxigenase-2 (COX-2) and pig-
ment-derived epithelium factor (PEDF) lowered IOP in catsFigure 3 Expression of reporter transgene after single intracameral inj
ﬂuorescent protein (GFP) to the anterior segment of the living rat (left
Images of rat frozen meridional sections at different time points were t
stable and long-term expression was monitored noninvasively with gon
gene transfer, represented by the presence of green cells occurred in liv
months in rats and for over two years in monkeys. Contralateral eyes inand protected death of RGC in rats, respectively (Barraza
et al., 2010; Miyazaki et al., 2011).
2.2. Silencing genes with short interfering RNA (siRNA)
Short interfering siRNAs are double stranded RNA molecules
21–24 nucleotides long. Inside the cells siRNA interacts with a
nuclease-containing multiprotein complex called RISC (RNA-
induced silencing complex). After binding to RISC, the siRNA
unwinds and pairs with its target mRNA; the RISC nuclease
cleaves the mRNA at the target site and this cleavage precipi-
tates a full degradation of the mRNA molecule which now is
unable to translate and produce the protein. siRNAs are thus
a powerful tool to silence unwanted genes and/or modulate
expression of downstream cascades. In initial experiments,
the perfusion of post-mortem human anterior segments with
a ﬂuorescent Cy3 labeled naked siRNA resulted in the en-
trance of the molecule into the trabecular meshwork tissue.
Subsequently, perfusion of the siRNA for the glucocorticoid
receptor (GR) did degrade its own RNA. Furthermore, in
the presence of dexamethasone (DEX), the GR siRNA modu-
lated also the expression of two DEX-induced genes (Myocilin
and Angiopoietin-like7). That is, silencing the receptor did
control the response of other genes induced by the glucocorti-
coid (Comes and Borra´s, 2007). Continuation of these studies
in living animals is showing positive delivery of siRNA by
intracameral injection to the trabecular meshwork of rats
(Lawrence et al., 2011). siRNA strategies are being developed
by several pharmaceutical companies. For glaucoma, a clinical
trial study presented at the recent ARVO meeting, showed
reduction of IOP upon administration of eye drops containing
a naked siRNA to the b2 adrenergic receptors (Ruz et al.,
2011). Studies coupling siRNA to different polymers andection of scAAV.GFP. Delivery of the reporter gene encoding green
) and living monkey (right) after single injection of the viral vector.
aken under a ﬂuorescent microscope (left). In the monkeys (right),
iophotography; images were taken with a fundus camera: positive
ing animals. The expression of the transgene lasted for about three
jected with phosphate-buffered saline (PBS) were negative.
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ciency of delivery of molecules (Huang and Liu, 2011).
3. Therapeutic gene targets and regulatory elements
In parallel to optimizing delivery vehicles that will carry genes
into the cells, our investigations and those of others are being di-
rected toward the identiﬁcation of gene targets which will lower
IOP by modifying the properties of the trabecular meshwork
cells. Because the function of any tissue is given by the expres-
sion of its genes, we ﬁrst looked at the most abundant genes ex-
pressed in the trabecularmeshwork under normal, physiological
conditions. To understand which genes would be relevant in the
cause and response of the cells to glaucoma, we performed sim-
ilar studies subjecting the trabecular meshwork tissue to glauco-
matous insults, such as elevated pressure and glucocorticoids.
For a human model, we used the perfused anterior segment per-
fusion where tissues from donor eyes, up to 35 h post-mortem
can be revived in organ culture.Most important in such amodel
is the fact that the gene response of a treated eye (OD) can be
compared to that of paired contralateral eye (OS) which has
an identical genetic background. The results are then not con-
founded by genetic differences among individuals (Fig. 4).
3.1. Identiﬁcation of genes that respond to glaucomatous insults
Microarray gene proﬁles performed with the RNA extracted
from trabecular meshwork of different individuals subjected
to an elevated IOP insult (Fig. 5) reveal a set of candidate genes
that we termed the ‘‘IOPmolecular biomarkers of the trabecular
meshwork’’ (Fig. 5) (Comes and Borra´s, 2009). This set of genes
has been cross-checked with other gene sets altered by treat-
ments with TGFb2, DEX and with those which are present onlyFigure 4 Human anterior segment perfusion model. Top: preparation
30–40 h postmortem are bisected at the equator and have their lens, iris
custom-made 2-cannula polycarbonate dish and secured by an open ring
maintained inside a CO2 incubator and perfused through one of the ca
second cannula is connected to a pressure transducer to monitor IOP. G
loop, that is intercalated between the syringes and organ culture chamin the trabecular meshwork from glaucoma patients (Borra´s,
2008). The result of the cross-cross-check yielded a gene list rep-
resenting a ‘‘molecular signature of glaucoma’’ (Borra´s, 2008).
An interesting ﬁnding from these studies is that genes altered
by high IOP could be divided into two subgroups, individual
and general responders (Comes and Borra´s, 2009). This ability
of some genes to respond differently to pressure in some individ-
uals provides the ﬁrstmolecular explanation to the different IOP
outcomes observed in the clinic. Interestingly, the 10 selected
genes identiﬁed in Fig. 5 are representative of several cellular
mechanisms that could affect outﬂow facility. Angiopoietin-like
7 and matrix metallopeptidases 1 and 12 (MMP1 and MMP12)
would affect the remodeling of the ECM; lysyl oxidase and ﬁb-
ulin 5 would affect the collagen-elastin network; a-B crystallin
and myocilin would be involved in stress response; matrix Gla
would affect the calciﬁcation state of the cell; podoplanin and
chemokine CXCL2 would affect unknown pathways involved
with the lymphatic and immune systems.3.2. Insertion of promoter elements to specify the site and extent
of gene expression
Two very important parameters to consider during the devel-
opment of a gene therapy regimen are tissue targeting and reg-
ulation of the expression of the gene. To avoid unwanted,
secondary effects due to gene-drug expression in surrounding
tissues, tissue-speciﬁc elements need to be introduced in the
gene promoter that would direct its expression only to the
wanted tissue. In addition, because gene-drugs could have a
very long duration of action (years), speciﬁc regulatory
elements need to be introduced in its promoter to be able to
turn them on and off at will. Ideally, a gene should be turned
on ‘‘automatically’’, in the presence of the glaucomatous in-of the postmortem human eyes for perfusion. Donor human eyes,
and vitreous removed. The anterior segment is then mounted to a
. Bottom: diagram of the perfusion system. The cultured chamber is
nnulas at constant ﬂow using a microinfusion syringe pump. The
ene drugs are injected through a HPLC pump equipped with a 20-ll
bers. Pumps are controlled by a custom-made computer program.
Figure 5 Identiﬁcation of pressure responder genes. (A) Diagram of the anterior segment perfusion model during an elevated IOP
experiment. To raise IOP, the ﬂow rate of one anterior segment is increased to achieve a DP of 35 mmHg. The ﬂow rate of the
contralateral eye remains at baseline. (B) Representative proﬁle of a human eye pair perfused at elevated pressure for three days. IOP is
continuously monitored by a pressure transducer and plotted with values obtained every 30 min. (C) Ten selected pressure responder genes
obtained from microarray proﬁles of pressured insulted trabecular meshworks (Affymetrix).
358 T. Borra´ssult, and turned off when the insult is no longer present. In
some cases, those inducible elements are very well deﬁned in
the literature as in the case of glucocorticoid response elements
(GRE, see below) (Aranda and Pascual, 2001). Other elements
needed for our glaucoma application need to be identiﬁed. A
number of such vectors are currently in the pipeline. A vector
targeting the trabecular meshwork is carrying the promoter of
a B-crystallin driving what is called a reporter gene for easy
detection in histological sections. The strategy of this tissue-
targeting vector is based on a comprehensive review of the
expression proﬁle of genes which are not expressed in tissues
facing the anterior chamber, and in the logistics that Ad vec-
tors do not penetrate the lens capsule (where aB-crystallin is
highly expressed). A vector responding to glucocorticoids is
carrying the glucocorticoid response element (GRE) in front
of a basal promoter and driving the MMP1 potential therapeu-
tic gene. Such a vector has been fully characterized and proved
to be speciﬁc in an animal model of hypertension (see section
4). An additional vector where the expression of the gene will
depend of whether elevated IOP is present, is also under devel-
opment. Since no IOP responding elements are yet deﬁned, the
beginning strategy has been to use the promoter of a general
pressure responder gene. The ﬁrst vectors contain the promot-
ers of matrix Gla and angiopoietin-like 7 driving a reporter
gene (secreted alkaline phosphatase) whose expression can be
measured biochemically along the time of high IOP exposure.
4. Application of gene therapy to treat steroid glaucoma
There is a very good rationale as to why the development of a
gene therapy regimen for steroid glaucoma could result in an
attractive and efﬁcient way to manage this type of ocular
hypertension. Two percent of the general population receives
glucocorticoid treatments. Thirty to 40% of the steroid-treated
patients develop elevated IOP (Armaly and Becker, 1965;Johnson, 1997). At the cellular level, it is well established that
steroid treatment leads to an increase of ECM material which
mimics that of primary angle glaucoma (Johnson et al., 1997).
This fact implies that several ECM targets could be used to
counteract the excessive build up. At the molecular biology le-
vel, the promoter sequences that respond to glucocorticoids
and turn on gene expression have been very well deﬁned in sev-
eral other cells. Putting all this information together led our
laboratory to develop a strategy where GRE elements would
be inserted in front of an ECM degradation gene. To then in-
sert such a cassette into a gene therapy vector and to inject the
vector intracamerally into the eye of an animal model of ocular
hypertension. The intent of the project was to induce a reorga-
nization of the ECM only in the presence of the glucocorticoid.
The ﬁnal goal was to reduce and prevent the steroid-induced
elevated IOP.
4.1. Selection of matrix metallopeptidase 1 (MMP1) to degrade
extracellular matrix (ECM) in the trabecular meshwork
Matrix metallopetidases (MMPs) comprise a family of zinc-
binding proteases known to play a key role in the turnover
of the ECM of the trabecular meshwork (Keller et al., 2009).
Previous studies on MMPs have shown that these enzymes
are able to increase aqueous humor outﬂow in perfused organ
cultures (Bradley et al., 1998). A member of this family is
MMP1, an interstitial collagenase which breaks down colla-
gens type I, II and III. Collagen type I is a main component
of the trabecular meshwork’s ECM scaffold. It constitutes
the central core of the trabecular meshwork beams. It was
known that treatment of trabecular meshwork with DEX in
organ culture conditions up-regulates collagen type I and
down-regulates MMP1 (Rozsa et al., 2006; Zhou et al.,
1998). Further, treatment of human trabecular meshwork cells
(HTM) with triamcinolone and prednisolone also down-
Gene therapy strategies in glaucoma and application for steroid-induced hypertension 359regulates MMP1 (Spiga and Borra´s, 2010). Therefore, MMP1
was selected as the gene target to investigate whether its
expression would counteract the steroid effect in living ani-
mals. Overexpressing MMP1 under glucocorticoid conditions
would serve not only to counteracting its down regulation,
but also would help reduce the ECM accumulation.
4.2. Engineering of an inducible gene therapy vector to facilitate
aqueous humor ﬂow
An adenoviral vector containing an inducible MMP1 cDNA
was generated using recombinant DNA techniques. The full
coding MMP1 cDNA (1410 nt), able to transcribe and trans-
late a pre-active protein, was ampliﬁed from laboratory
HTM cells overexpressing MMP1. The basic promoter and
GRE sequences, able to induce a downstream gene, were ex-
tracted from a commercial vector. Fusion of these two DNA
fragments formed the expression cassette which will be incor-
porated into the viral vector Adh.GRE.MMP1. A second vec-
tor producing a mutated MMP1 protein was also generated
and used as negative control. This mutated MMP1 containedFigure 6 Generation and assays of inducible gene therapy vectors
representation of glucocorticoid-inducible viral vectors expressing reco
MMP1 only after DEX binding to the GRE sequences in the promoter.
cells. Cells were infected with wild-type and mutant viral vector, treated
MMP1 RNA assayed by TaqMan PCR showed a very signiﬁcant incre
As well, levels of MMP1 protein assayed by western blots were highl
activity of secreted recombinant MMP1 in HTM cells. Cells were inf
harvested. Aliquots of the cell media were activated and incubated w
stained with Comassie blue to assay intact or degraded collagen. Only a
wild-type vector were able to break down collagen (lane 2).one nt substitution at the catalytic binding site which leads
to improper folding and destroys its catalytic activity
(Adh.GRE.mutMMP1) (Fig. 6A) (Spiga and Borra´s, 2010).
Response of the potential vectors to glucocorticoids was
extensively characterized in primary cell and organ cultures
conditions. As expected, infection of the cultures with both
vectors induced high levels of MMP1 mRNA and protein
(Fig. 6B). However, only the protein produced by the wild-
type MMP1 had collagenase activity and was able to degrade
collagen. This important property was tested in several as-
says. In a classical assay, puriﬁed rat collagen was incubated
with the activated conditioned media of cells infected with
MMP1 vectors and ran in polyacrylamide gels. Rat collagen
was seen degraded only in the gel lane which had been
loaded with the activated wild-type protein (Fig. 6C). A
more sophisticated technology, state of the art assay, the
ﬂuorescence resonance energy transfer (FRET), utilized an
MMP substrate peptide labeled with a ﬂuorophore and a
quencher. Cleavage of the peptide with MMP1, which re-
leases the ﬂuorophore and is read in a ﬂuorophotometer,
was observed only in the incubation of the wild-type-infectedfor the treatment of steroid-induced hypertension. (A) Schematic
mbinant MMP1. Wild-type (active) and mutant vectors expressing
(B) DEX-induced overproduction of recombinant MMP1 in HTM
with 0.1 lM DEX and harvested for RNA and protein. Levels of
ase in the DEX treated cells compared to untreated controls (left).
y increased in the treated cells (right). (C) Enzymatic collagenase
ected and treated with DEX as in B and conditioned media was
ith rat tail native collagen for 2 h. Samples were run on gels and
ctivated samples obtained from DEX-treated cells infected with the
360 T. Borra´sconditioned media with the FRET peptide. Lastly, by immu-
nohistochemistry, double staining of the human perfused
trabecular meshwork with MMP1 and collagen type I anti-
bodies revealed degradation of collagen in the areas where
levels of MMP1 were higher (Spiga and Borra´s, 2010).
Another important property of the Adh.GRE.MMP1 vec-
tor was the fact that overexpression of the MMP1 transgene
could be synchronized with the administration of DEX. Upon
infection of HTM cells with the vector, MMP1 expression was
consecutively on and off coinciding with the treatment and
withdrawal of the glucocorticoid. For a gene therapy drug
application, this characteristic is of upmost importance. Deg-
radation of the ECM in steroid-induced hypertension will oc-
cur only in the presence of the steroid.
Altogether the generated vector Adh.GRE.MMP1 seemed
to contain all characteristics required for its application to
an steroid-induced in vivo model.
4.3. Sheep model of steroid-induced ocular hypertension
The laboratories of Drs. Oscar Candia (Mount Sinai School of
Medicine) and Rosana Gerometta (Universidad Nacional del
Nordeste, Corrientes Argentina) have recently developed a
model of glucocorticoid induced ocular hypertension in Cor-
riedale sheep (Ovis aries) (Gerometta et al., 2009). Topical
application of two drops of 0.5% prednisolone acetate (Ultra-
corteno, Novartis) 3· daily into one eye of the sheep results in
a 2.5· IOP increase within 1–2 weeks. IOP values, read with
a Perkins applanation tonometer, are between 9–11 mmHg atFigure 7 Adh.GRE.MMP1 injection lowers steroid-induced hypert
values from two sheep: (A) sheep injected in one eye with the active
mutant Adh.GRE.mutMMP1 (B). Contralateral eyes also treated with
IOP measurements. Only the eye injected with the active gene therapy
steroids.baseline and raise to 25–28 mmHg. Pressures of the contralat-
eral eye, receiving artiﬁcial tears, remain at baseline levels. In
contrast to humans, this elevation of IOP occurs in 100% of
the glucocorticoid treated animals. The elevated IOP is main-
tained during a 4 week application of the prednisolone drops,
persists after discontinuation of the treatment, and returns to
baseline levels over the course of one to three weeks
(Gerometta et al., 2009).
An elevation of IOP is also obtained by a single sub-Tenon
injection of triamcinolone. One milliliter injection of triamcin-
olone acetonide (40 mg/ml, Bristol-Myers Squibb) is adminis-
tered under topical anesthesia using a 30G needle. The
injection is performed to create a juxta-sclera depot rather that
an intra Tenon injection (Gerometta et al., 2010). Pressures of
the injected eye are increased 2· at day 4 post-injection and
remain high for about 2–3 weeks.
The docile nature of these animals together with their 100%
response to the steroid makes the sheep model ideal for studies
of gene therapy treatment of steroid-induced hypertension.
4.4. Lowering IOP after glucocorticoid administration with an
inducible viral vector
In a study involving a total of six sheep, baseline pressures
were taken for one week and prednisolone was administered
daily afterward in both eyes. At four days post-prednisolone
treatment, when the pressures had risen to 2· baseline levels,
one eye of each sheep received an intracameral injection of 1 of
3 adenoviral vectors while the contralateral eyes remainedension in sheep. Representative corticosteroid regimen and IOP
Adh.GRE.MMP1. (B) Sheep injected in one eye with the inactive
corticosteroid, remained uninjected. (C) Representative plots of the
vector experimented a decrease from the elevated IOP induced by
Figure 8 Prevention of steroid-induced hypertension. Pre-injection of the active gene therapy vector Adh.GRE.MMP1 prevents the
elevated IOP induced by the corticosteroid. Contralateral uninjected eye received two corticosteroid treatments and induced elevated IOP.
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h.GRE.MMP1) (Fig. 7A), the second vector carried the mu-
tated form of the protein lacking the active catalytic site
(Adh.GRE.mutMMP1) (Fig. 7B), and the third vector was
‘‘empty’’, that is, carrying no transgene (Ad.Null). The contra-
lateral eyes were left uninjected. The IOP stayed elevated in all
eyes that were either uninjected or injected with the control
vectors for the duration of the prednisolone instillation How-
ever, in eyes injected with the active MMP1 the elevated IOP
returned to the lower baseline values two days after the viral
injection (Gerometta et al., 2010). Low pressures of the wild-
type injected eyes persisted for approximately 10–15 days long-
er, which correspond with the published data of the duration
of the expression of adenoviruses in living animals (Fig. 7)
(Borra´s et al., 2001; Kee et al., 2001).
An additional four sheep received sub-Tenon injections of
triamcinolone in both eyes. Four days later, IOP increased
from 11.3 ± 0.3 to 22. ± 0.8 mmHg in one eye and, from
9.7 ± 0.2 to 22.1 ± 0.2 mmHg in its contralateral. One eye
of each sheep was then injected with the wild-type Ad-
h.GRE.MMP1 while the paired eye was injected with the vec-
tor carrying the mutated form of the protein (Adh.GRE.
mutMMP1). Two to three days after viral injections, IOP
was signiﬁcantly reduced in the eyes injected with the active
MMP1 (11.6 ± 0.4) but remained elevated in the eyes injected
with vector carrying the mutant protein which lacks the cata-
lytic site (22.1 ± 0.2 mmHg). However, in contrast with the
prednisolone experiments, where the reduction was maintained
for almost two weeks, the reduction observed with the wild-
type vector lasted just for three to four days (Gerometta
et al., 2010). The causes of the short reduction after triamcin-
olone injection are not known and need further investigation.
Perhaps, variability in the formation of the depot and release
of the steroid plays a role in overriding the effect of the vector.
None of the sheep eyes injected with any of the adenoviral
vectors showed adverse clinical signs. There were no signs ofhyperemia or inﬂammation, and the corneas remained clear.
This ﬁrst case of lowering elevated IOP by a gene therapy vec-
tor in a large animal provides the initial steps for the develop-
ment of a new avenue of treatment for ocular hypertension
induced by steroids.
4.5. Prevention of steroid-induced elevated pressure by pre-
injection with an inducible viral vector
In addition to lowering the steroid-induced IOP, the adenovi-
ral vector which delivers the active MMP1 is also able to pre-
vent the steroid-induced IOP elevation. In two independent
experiments, Adh.GRE.MMP1 was injected at day 0 and pred-
nisolone instillation started two or three days after injection.
Pressure elevation did not occur until 12 to 15 days post-viral
injections, in concordance with the duration of expression of
the transgene in an adenoviral vector (Fig. 8).
Similarly, the same Adh.GRE.MMP1 vector was able to
avoid the doubling pressure increase induced by the triamcino-
lone. At day 0, with baselines pressures of 9.4 ± 0.1 mmHg, the
eyes of two sheep were injected with the active viral vectors fol-
lowed by triamcinolone injections one day later. Pressures re-
mained close to baseline levels for four days, reached a mid-
value of 12.9 ± 0.5 mmHg at ﬁve days and attained the ex-
pected triamcinolone doubling response of 21.3 ± 0.3 mmHg
at 11 days. These ﬁndings indicate that during the time the virus
is producing the therapeutic protein (10–15 days), there is a
counteractive, protective action that impedes the steroid to exert
its full potential.
5. Conclusion and future directions
During the past few years, there have been important advances
in the use of gene therapy for the treatment of eye diseases.
Without a doubt, the most important success has been the res-
362 T. Borra´storation of vision by the replacement of the RPE65 gene to pa-
tients of Leber congenital amaurosis (Stein et al., 2011). In
addition of demonstrating efﬁcacy by delivering the wild-type
gene, these clinical trials have served to validate the safety of
the AAV viral vector for the use of gene therapy in the human
eye. The importance of this safety issue cannot be underesti-
mated. Regarding glaucoma, we have made considerable pre-
clinical advances in all four relevant fronts: potential
therapeutic genes with regulatory elements, safe and efﬁcient
delivery vectors, animal models, and signiﬁcant improvements
in animal evaluation technology (from physiology to imaging).
There are now a considerable number of genes with neuropro-
tective properties under study in several laboratories. These
genes are being tested in AAV vectors, which transduce
RGC cells very efﬁciently. There are also, as we saw above,
potentially therapeutic genes controlled by regulatory elements
that could target the trabecular meshwork and lower elevated
IOP. We do have a second generation AAV vector to trans-
duce the outﬂow tissue and we are beginning to have good ani-
mal models to test their efﬁciency. An important body of work
is ahead and we are not yet ready. However, the general
outlook is that the gene therapy approach for glaucoma looks
much more feasible now than what it did ﬁve years ago. We
can only envision that the next ﬁve years will be as productive
and will take us to the trial of the ﬁrst gene therapy drug for
glaucoma in the clinical setting.Acknowledgments
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